Related Experiment Videos
Combinations of drugs
1Department of Neurology, University Hospital, Kantonsspital Basel, Switzerland.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|July 1, 1996
Summary
Combining therapies for relapsing-remitting MS may improve outcomes. Future research should explore combinations like recombinant Interferon beta with immunosuppressants or Copolymer I.
Area of Science:
- Neuroimmunology
- Clinical Therapeutics
- Multiple Sclerosis Research
Background:
- Current treatments for relapsing-remitting MS (RRMS) include recombinant Interferon beta (rIFN beta)-Ib and -Ia, Copolymer I (COP I), and non-specific immunosuppressants, offering partial efficacy.
- The limited effectiveness of single-agent therapies prompts investigation into combination treatments for RRMS.
Purpose of the Study:
- To explore the theoretical basis and potential benefits of combining therapeutic agents for relapsing-remitting MS.
- To outline criteria for selecting combination partners and suggest strategies for clinical evaluation.
Main Methods:
- Discussion of theoretical background for combination therapies.
- Criteria for selecting combination partners: proven efficacy, distinct mechanisms of action, and side effect profiles.
- Proposal for evaluation in early phase II and phase III studies, utilizing surrogate markers like MRI findings.
Main Results:
- Recombinant Interferon beta combined with non-specific immunosuppressants (e.g., Azathioprine, Methotrexate) or Copolymer I are potential candidates for near-future phase II/III studies.
- Combinations involving agents in early single-treatment development may offer future therapeutic promise.
Conclusions:
- Combination therapy holds potential for improved efficacy in RRMS treatment.
- Strategic selection and rigorous evaluation of combination regimens are crucial for advancing MS therapeutics.